We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




German Partners to Develop Biomarker Platform for Targeted Cellular Therapies

By LabMedica International staff writers
Posted on 05 Mar 2012
Two German biotech companies are cooperating in a personalized medicine project to develop a predominantly tissue-based biomarker strategy for the treatment of solid cancers with cellular and / or gene therapeutics.

The partnership will exploit the complimentary assets of apceth GmbH & Co. More...
KG (Munich, Germany), and Indivumed GmbH, (Hamburg, Germany). apceth is known for its development and clinical application of pioneering stem cell and gene therapies, particularly for the treatment of malignant diseases. Indivumed maintains a comprehensive tumor database and high-quality biobank for the development of new cancer diagnostics and therapies, and provides state-of-the-art services for biomarker discovery based on viable primary human biospecimens.

The goal of the new project is to predict the response to targeted cellular/ gene therapy in different cancer types and to stratify patients to provide a more individualized cancer treatment with apceth’s innovative cell and cell-based gene therapeutics.

The partners have indicated that the combination of apceth’s therapeutic approach and Indivumed’s biomarker platform has the potential to drive future cancer therapeutics and pharmaceutical innovation, thereby making the promises for personalized medicine a reality.

Related Links:
apceth GmbH & Co. KG
Indivumed GmbH




Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Immunofluorescence Analyzer
IFA System
New
Automatic CLIA Analyzer
Shine i6000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Mycobacterium tuberculosis bacteria seen with a scanning electron microscope (Credit: CDC PHIL)

Antibody Blood Test Identifies Active TB and Distinguishes Latent Infection

Active tuberculosis (TB) remains a leading cause of death and illness worldwide, yet distinguishing contagious disease from latent infection continues to challenge clinicians. Standard screening tools... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.